research Trichoscopic Findings of Frontal Fibrosing Alopecia
Trichoscopy is useful for diagnosing Frontal Fibrosing Alopecia.
Search
for
Sort by
Research
720-750 / 1000+ results 
research Pharmacological Treatment of Alopecia
Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.
research Advances in the genetic understanding of hypohidrotic ectodermal dysplasia
Scientists now better understand the genetics of hypohidrotic ectodermal dysplasia, leading to more accurate diagnoses and potential new treatments.
research Minoxidil Use in Alopecia
Minoxidil helps stimulate hair growth and enlarge small follicles in common hair loss, but doesn't stop it, and its effects can be boosted when combined with finasteride.
research British Hair and Nail Society
Men with a certain type of hair loss often use facial moisturizers, and a specific antibiotic treatment may help another hair condition.
research Buschke-Ollendorff syndrome
Buschke-Ollendorff syndrome is a rare genetic disorder causing skin and bone changes, with some cases also showing ADHD or developmental delays.
research Trichodystrophies: A hair-raising differential diagnosis
The guide helps doctors diagnose hair problems by suggesting a thorough patient history, physical exams, and various diagnostic tools.
research Limited Effectiveness of Platelet-Rich-Plasma Treatment on Chronic Severe Alopecia Areata
Platelet-rich plasma treatment is not very effective for chronic severe alopecia areata.
research HIV infection mimicking autoimmune disorder
A girl with symptoms like an autoimmune disorder actually had HIV and a fungal infection, which was hard to diagnose and treat, leading to her death.
research FEATURES
Pharmacists play a key role in helping patients use over-the-counter products correctly, including those for hair regrowth and smoking cessation.
research Aesthetic medicine treatments for oncology patients — a narrative literature review
Aesthetic treatments can safely improve cancer patients' quality of life with oncologist approval.
research Case Report: Secondary syphilitic alopecia following non-penetrative sexual contact: a case of initial misdiagnosis
Syphilis can cause hair loss even without penetrative sex, but treatment can fully restore hair.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
Rituximab can cause skin issues, but baricitinib may help improve them.
research Patient-reported Outcomes of Adverse Events After Perioperative Chemotherapy for Breast Cancer: A Prospective Observational Study
Some side effects of breast cancer chemotherapy, like neuropathy and nail loss, can last long after treatment.
research Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
research Hair for the Long Haul: Alopecia Areata Cases and Considerations
JAK inhibitors are effective for long-term management of alopecia areata.
research Alopesi Tedavisinde Kullanılan İlaç Tedavileri ve Yeni Yaklaşımlar
Alopesi tedavisinde ilaçlar saç büyümesini teşvik eder ve yeni yaklaşımlar umut vaat eder.
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.
research Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
Baricitinib significantly regrows hair in teens with severe alopecia areata.
research Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
research Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
Tofacitinib is effective and safe for treating severe alopecia areata.
research Patient-reported outcomes of adverse events after perioperative chemotherapy for breast cancer: A prospective observational study
Some side effects of breast cancer chemotherapy last longer than others, and patient feedback can help improve care.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response
Baricitinib effectively regrows hair in severe alopecia areata cases.
research The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review
Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
research Patient Validation of Estimation of Health Utility Values in Alopecia Areata
Patients with Alopecia Areata are willing to trade life duration for better quality of life.
research Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
The study within the ALLEGRO clinical trial program assessed 832 patients with alopecia areata (AA) to identify predictors of long-term scalp hair regrowth following ritlecitinib treatment. Key predictors for achieving a SALT score ≤20 at 24 months included baseline SALT score, SALT score at Month 6, non-AT/AU type, duration of AA since diagnosis, and duration of significant scalp hair loss at baseline. These findings indicate that certain patient characteristics can predict treatment outcomes, which may help optimize treatment decisions for AA. However, the predictive models are not yet validated for clinical practice and should not replace professional medical judgment.
research Medical Physics in Aesthetic Medicine: Innovations and Techniques for Cosmetic Procedures in 2025
Aesthetic medicine is rapidly advancing with new technologies for safer, personalized, and less invasive treatments.